Bayer concentrates on long-term growth:
This article was originally published in Clinica
Executive Summary
Bayer is pursuing "an even more expansionary course than before", with extra money invested in R&D, according to its chairman, Manfred Schneider. The chief beneficiaries of increased investment are the healthcare - which includes diagnostics - and agriculture sections, which will share 70% of the DM4.1 billion ($2.2 billion) R&D budget for 1998. The German company had sales of DM14.3 billion in the first quarter, up 8% on the previous period. Net income rose by 21% to DM864 million.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.